Alzheimer’s and Down Syndrome Vaccine Candidate Advances
A clinical-stage biopharmaceutical company announced 2
clinical milestones related to ACI-24, an anti-Abeta vaccine candidate against
Alzheimer's disease and the Abeta-related cognitive decline in Down Syndrome.
ACI-24 is a liposomal therapeutic anti-Abeta vaccine
candidate, which generates antibodies specific to disease-causing
conformations.
The vaccine is designed by AC Immune to stimulate a
patient's immune system to produce antibodies that specifically target the
oligomeric and fibrillary Abeta proteins, to prevent plaque accumulation and to
enhance plaque clearance.
Andrea Pfeifer, the CEO of AC Immune, said in a press
release, "We are delighted with the progress of ACI-24, which is currently
the only clinical-stage vaccine targeting the associated Abeta-induced
cognitive decline in people with Down Syndrome.”
“Vaccines are potentially an important option for the
treatment and prevention of neurodegenerative diseases."
Comments
Post a Comment